Agilent Technologies Inc. has introduced SurePrint G3 CGH+SNP cancer catalog microarrays, addressing the growing need of researchers to detect both copy number and copy-neutral aberrations in cancer ...
Three genomic tests separately predict the likelihood that a patient's breast cancer will reoccur after surgery without additional treatment, and the cancer's vulnerability to chemotherapy or hormone ...
Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non–Small-Cell Lung Cancer Identifying sources of variation in expression microarray data and the effect of variance in gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results